vaccines

MDPI

Review

Frontiers in mRNA Vaccine Research: Integrating Epitope Prediction, Structural Biology, and Clinical Translation

Matthias Magoola[1], Sarfaraz K. Niazi[2,*]

[1] DEI Biopharma, Kampala, Uganda. mm@dei.bio
[2*] Correspondence: College of Pharmacy, University of Illinois, Chicago, IL 60612; sniazi3@uic.edu

Abstract: The emergence of mRNA vaccine technology has revolutionized vaccine development, as demonstrated during the COVID-19 pandemic. With epitope-based design approaches, mRNA vaccines offer unprecedented potential for developing targeted immunotherapies against various pathogens. This review examines the status of epitope-based mRNA vaccine development, providing a comprehensive analysis of computational and experimental methodologies for epitope identification, structural considerations for optimal design, and delivery technologies. We critically evaluate the performance of current prediction tools and validation approaches while presenting diverse case studies of epitope-based vaccines in various stages of development across viral, bacterial, and parasitic pathogens and cancer applications. These examples span from preclinical studies to FDA-approved products, such as Moderna's RSV mRNA-1345 (NCT05127434) and personalized neoantigen cancer vaccines, with detailed analysis of epitope selection strategies, structural arrangements, and clinical data. While significant progress has been made, challenges in epitope prediction accuracy, optimal epitope arrangement, and translation of in silico predictions to in vivo efficacy remain. We also discuss the regulatory landscape for these novel vaccine constructs and emerging approaches, including multi-pathogen epitope mosaics, AI-driven design, and real-world evidence integration, pointing toward a new era of rational vaccine development against infectious diseases and cancer.

Keywords: Epitope; mRNA; vaccine; viral; bacterial; therapeutic; cancer.

Academic Editor: Firstname Lastname

Received: date
Revised: date
Accepted: date
Published: date

Citation: To be added by editorial staff during production.

Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Infectious disease outbreaks continue to pose serious global health challenges, as exemplified by the COVID-19 pandemic and the emergence of zoonotic viruses such as avian influenza, MERS-CoV, and Lassa virus. While vaccination has historically been one of the most transformative public health interventions—drastically reducing morbidity and mortality from numerous diseases, including measles, polio, hepatitis B, and yellow fever—traditional vaccine platforms face several critical limitations. Conventional approaches, including inactivated, live attenuated, viral vector-based, and protein subunit vaccines, although effective in many cases, are often hindered by prolonged development timelines, cold chain requirements, scalability issues, risk of reversion to virulence, and insufficient intrinsic immunogenicity necessitating adjuvants.

The urgency for more agile and precise vaccine technologies has accelerated the development of next-generation platforms. Among these, mRNA vaccines have gained

prominence due to their rapid manufacturing capabilities, potent immunogenicity, and capacity to be tailored against specific antigens using computationally guided design. The success of mRNA-based vaccines against SARS-CoV-2 has validated this platform as a viable and scalable strategy, especially when integrated with rational immunogen selection.

A major challenge in developing vaccines against rapidly evolving RNA viruses—including influenza, HIV, HCV, dengue, and noroviruses—lies in their high mutation rates and antigenic variability, which enable immune escape. Immune evasion strategies are not confined to viruses; numerous bacterial and parasitic pathogens, including species of Neisseria, Treponema, Anaplasma, Trypanosoma, Plasmodium, and many other bacterial and protozoal genera, employ antigenic variation to evade host immunity, further complicating vaccine development strategies.

To address these challenges, epitope-based vaccine design has emerged as a rational and promising strategy. Unlike conventional vaccines that utilize whole pathogens or full-length antigens, epitope-based vaccines focus on specific immunogenic regions of pathogen proteins essential for immune recognition. This precision approach excludes non-immunogenic or potentially reactogenic components and enables targeting conserved epitopes that are less susceptible to mutation. When delivered through mRNA technology, these epitopes can be efficiently expressed in vivo, enhancing antigen presentation and facilitating both humoral and cellular immune responses.

The convergence of reverse vaccinology, immunoinformatics, and structural biology now enables the identification of B-cell and T-cell epitopes with high population coverage and MHC binding potential while minimizing off-target effects. Contemporary computational tools can rapidly screen entire pathogen proteomes to identify conserved, immunodominant, and structurally accessible epitopes. These predictions are further refined through molecular modeling, docking simulations, and in vitro validation approaches.

This review examines the current landscape of epitope-based mRNA vaccine development, focusing on diverse case studies that highlight different approaches and development stages. We analyze how computational methods facilitate the identification of immunogenic epitopes across multiple pathogens and discuss how structural biology informs epitope optimization. Additionally, we evaluate manufacturing challenges clinical trial data and explore emerging technologies for improving epitope-based mRNA vaccine design.

2. Design Considerations in Epitope-based mRNA Vaccines

2.1. Epitope Identification and Validation Strategies

Effective epitope-based vaccine design begins with identifying immunogenic epitopes capable of eliciting protective immune responses. This process integrates computational prediction with experimental validation in an iterative workflow. Modern epitope prediction employs multiple criteria: antigenicity (recognition by the immune system as foreign), conservation (preservation across strains to achieve cross-protection), population coverage (recognition by diverse HLA alleles ensuring broad efficacy), and absence of allergenicity or toxicity profiles that might compromise safety.

Contemporary computational tools have transformed epitope identification, enabling rapid screening of pathogen proteomes. Advanced algorithms incorporate machine learning approaches trained on experimentally validated datasets to improve prediction accuracy. T-cell epitope prediction focuses on peptides binding to MHC molecules (class I for CD8+ T-cell epitopes, class II for CD4+ T-cell epitopes) using sequence-based methods, structure-based algorithms, and machine learning models. B-cell epitope prediction remains more challenging, requiring assessment of linear epitopes through sequence

properties like hydrophilicity and flexibility, while conformational epitopes demand structural data to identify spatially adjacent residues.

Several computational platforms support epitope identification for vaccine design (see Table 1). NetMHCpan-4.1 employs neural networks to predict MHC-I binding with remarkable accuracy (AUC 0.91-0.95), though its application remains limited to particular species [49]. The IEDB 2023 provides a comprehensive resource incorporating multiple prediction methods, though data gaps persist for rare HLA alleles [50]. BepiPred-2.0 utilizes random forest algorithms for B-cell epitope prediction with moderate performance (AUC 0.57-0.62), struggling particularly with conformational epitopes [51]. Recent advances in machine learning approaches, particularly the integration of AlphaFold-Multimer-based structural predictions, have begun to address these limitations by incorporating three-dimensional conformational data into epitope prediction pipelines.

Computational predictions require rigorous experimental validation through complementary methods. Binding assays quantify peptide-MHC interactions via competitive binding, direct binding, or surface plasmon resonance techniques to measure binding kinetics. Cellular assays evaluate T-cell responses through IFN-γ ELISPOT, intracellular cytokine staining, and MHC-peptide tetramer staining. Humoral response validation employs ELISA, peptide arrays, and neutralization assays to confirm functional antibody responses. Structural validation through X-ray crystallography, cryo-EM, hydrogen-deuterium exchange mass spectrometry, and molecular dynamics simulations provide critical insights into epitope stability and recognition dynamics.

2.2. mRNA Platform Design and Manufacturing Considerations

mRNA vaccines utilize synthetic messenger RNA to induce cells to produce antigenic proteins that stimulate immune responses. Critical components in mRNA design include a 7-methylguanosine cap structure to enhance translation efficiency and reduce innate immune recognition, optimized 5' and 3' UTRs affecting mRNA stability and translation efficiency, codon optimization aligned with host translational machinery, modified nucleosides such as Ψ and m1Ψ to reduce immunogenicity and increase stability, and a poly(A) tail of approximately 100-150 nucleotides to enhance longevity in the cellular environment. The ORF encodes multiple epitopes connected by appropriate linkers for epitope-based constructs, often incorporating signal peptides for secretion or targeted cellular localization.

Manufacturing epitope-based mRNA vaccines presents unique challenges distinct from conventional vaccine platforms. Large-scale GMP-compliant production requires highly purified enzymes, nucleotides, and cap analogs for in vitro transcription, with batch-to-batch consistency remaining a critical consideration. Capping efficiency significantly impacts translation, with co-transcriptional capping generally preferred over post-transcriptional methods for manufacturing scale-up. LNP formulation requires precise control of lipid ratios, mixing conditions, and particle size distribution to ensure consistent cellular uptake and tissue distribution. Quality control metrics specific to epitope-based constructs must verify mRNA integrity and the correct incorporation of all epitope sequences in the proper orientation.

Delivery systems for mRNA vaccines continue to evolve beyond traditional lipid nanoparticles. Recent innovations include ionizable lipid nanoparticles with tissue-targeting capabilities, polymeric nanocarriers offering more excellent stability, and exosome-based delivery systems that may enhance cellular uptake and reduce immunogenicity. These delivery technologies significantly impact the biodistribution, cellular uptake, and immunogenicity of epitope-based mRNA vaccines, underscoring the importance of optimizing both the mRNA construct and its delivery vehicle.

2.3. Glycosylation and Immune Modulation in Epitope Design

A critical consideration in epitope-based vaccine design is the impact of post-translational modifications, particularly glycosylation, on epitope accessibility and immune recognition. Many viral envelope glycoproteins, including HIV Env, SARS-CoV-2 spike protein, and influenza HA, employ glycan shielding as an immune evasion strategy. Dense glycan arrays create a "glycan shield" that masks potential epitopes from antibody recognition [74].

Epitope-based approaches offer strategic advantages by specifically targeting glycan-free regions or conserved sites of vulnerability where glycan holes exist. For HIV immunogen design, the eOD-GT8 60mer construct deliberately incorporates engineered glycosylation patterns that focus antibody responses toward the CD4 binding site while shielding immunodominant but non-neutralizing epitopes [35]. Similarly, RSV F protein epitope vaccines maintain critical neutralizing epitopes at antigenic sites Ø and II that are minimally affected by glycosylation.

Advanced glycoengineering strategies include targeted glycan deletion to expose conserved epitopes, incorporating homogeneous glycoforms to enhance antigen presentation, and repositioning to focus immune responses toward desired epitopes. These approaches require sophisticated structural analysis and glycobiology expertise but offer significant potential for strengthening epitope-based vaccine efficacy through precise modulation of glycan-mediated immune recognition [75].

3. Case Studies of Epitope-based mRNA Vaccines

The following case studies represent diverse approaches to epitope-based mRNA vaccine development across viral, bacterial, and parasitic pathogens and cancer applications from various global research groups and companies.

3.1. Viral Pathogens

mRNA-1345: RSV F Protein Epitope Vaccine

Respiratory Syncytial Virus (RSV) remains a significant cause of lower respiratory tract infections globally, particularly in infants and older adults. Moderna's mRNA-1345 (NCT05127434) represents one of the most advanced epitope-based mRNA vaccines to receive regulatory approval. The vaccine targets the prefusion conformation of the RSV F glycoprotein, which contains conserved epitopes necessary for viral entry. Unlike previous RSV vaccine candidates utilizing post-fusion F protein, mRNA-1345 focuses on epitopes in the prefusion conformation recognized by potent neutralizing antibodies. Key epitopes were identified through structural antibody-bound prefusion F protein analysis, sequence conservation analysis across RSV strains, and immunogenicity screening in animal models. The design incorporated stabilizing mutations (S190F, V207L) that lock the F protein in its prefusion conformation, preserving neutralizing epitopes at antigenic sites Ø and II [30].

With optimized codon usage, the mRNA construct expresses a membrane-anchored trimeric prefusion F protein. Phase 3 clinical trials demonstrated 83.7% efficacy against RSV-associated lower respiratory tract disease with two or more symptoms in adults aged 60 years and older [31]. Based on these findings, the FDA granted approval for mRNA-1345 (marketed as Abrysvo) in August 2024, marking a significant milestone for epitope-focused mRNA vaccines.

HIV-1 Conserved Element mRNA Vaccine

HIV-1 represents one of the most formidable targets for vaccine development due to its extraordinary genetic diversity and immune evasion mechanisms. Researchers at IAVI and Scripps Research developed an mRNA vaccine approach targeting conserved epitopes of the HIV-1 envelope glycoprotein [33, 34]. The strategy focused on germline-targeting immunogens designed to activate specific B-cell precursors with the potential to

develop into broadly neutralizing antibodies. The mRNA-expressed immunogen, eOD-GT8 60mer (NCT03547245), was intended as a nanoparticle displaying 60 copies of an engineered outer domain of HIV-1 gp120 optimized to bind to germline precursors of the VRC01 class of bNAbs that target the CD4 binding site [35].

The Phase 1 IAVI G001 trial demonstrated that the mRNA-delivered eOD-GT8 60mer successfully activated rare B-cell precursors with neutralizing potential in 97% of vaccine recipients [36]. This represents a proof-of-concept for germline-targeting vaccine design and establishes a foundation for sequential vaccination strategies against HIV-1.

Tetravalent Dengue mRNA Vaccine

Dengue virus presents unique challenges for vaccine development due to its four distinct serotypes and ADE potential during secondary infections. Mukhtar et al. designed a tetravalent modified nucleotide mRNA vaccine targeting conserved epitopes from NS1, prM, and domain III of the envelope protein from dengue virus isolates [32]. The design process incorporated conservation analysis using Shannon entropy to identify highly conserved regions, predict linear B-cell epitopes using multiple computational tools, and identify T-cell epitopes with broad HLA coverage. The final construct included epitopes showing 100% conservation across the four DENV serotypes.

The epitopes were arranged with strategic linkers (GPGPG for B-cell epitopes, AAY for T-cell epitopes) to ensure independent folding and processing. While this tetravalent dengue mRNA vaccine remains in preclinical development, initial immunogenicity studies demonstrated balanced responses against all four serotypes without evidence of enhancement.

mRNA-1230: Multi-pathogen Respiratory Virus Vaccine

A compelling example of mosaic vaccine development is Moderna's mRNA-1230 (NCT05558307), a combination vaccine targeting SARS-CoV-2, influenza, and RSV in a single construct. This prototype represents the practical application of multi-pathogen epitope strategies, combining immunodominant epitopes from three major respiratory viruses. The vaccine incorporates the SARS-CoV-2 spike protein, quadrivalent influenza HA antigens, and the prefusion stabilized RSV F protein [76].

The design employs a sophisticated epitope arrangement that maintains the structural integrity of each antigen while ensuring appropriate processing and presentation. Early Phase 1/2 clinical data has demonstrated robust immune responses against all three pathogens, with antibody titers comparable to those elicited by individual vaccines. This approach illustrates the potential of epitope-based mRNA platforms to revolutionize vaccination schedules by protecting against multiple diseases with fewer administrations. Optimization of epitope selection and arrangement continues to enhance the efficacy and manufacturability of this promising multi-pathogen approach.

3.2. Bacterial and Parasitic Pathogens

MTbVAC-mRNA: Tuberculosis Epitope Vaccine

Tuberculosis remains one of the world's deadliest infectious diseases, with existing BCG vaccines providing limited protection. BioNTech's MTbVAC-mRNA represents a novel approach targeting this bacterial pathogen through immunodominant T-cell epitopes [62]. The selection process involved immunopeptidomics analysis of MTB-infected cells to identify naturally processed and presented epitopes, focusing on those recognized by T-cells from individuals with latent TB infection. The construct incorporates CD4+ T-cell epitopes and CD8+ T-cell epitopes from key MTB antigens (Ag85B, ESAT-6, CFP-10) with optimized linker sequences to ensure proper processing and presentation.

MTbVAC-mRNA entered Phase 1 clinical trials in 2023, with preliminary data showing robust T-cell responses in vaccinated individuals [63]. Animal studies demonstrated superior protection compared to the BCG vaccine, significantly reducing bacterial burden

in challenge models. This would represent the first mRNA vaccine against a bacterial pathogen to advance through clinical development.

Plasmodium falciparum multi-epitope mRNA Vaccine

Malaria vaccine development has been hampered by the complex life cycle of Plasmodium parasites and their antigenic diversity. Recent efforts have focused on epitope-based approaches targeting conserved pre-erythrocytic and blood-stage antigens regions. A novel multi-epitope mRNA construct incorporates B-cell epitopes from CSP, TRAP, and MSP1, along with T-cell epitopes providing broad population coverage [73].

Computational epitope selection utilized protein microarray data from naturally acquired immunity in endemic regions, identifying epitopes recognized by protective antibodies. The mRNA construct employs the self-amplifying RNA platform to enhance antigen expression and immunogenicity. In preclinical testing, the vaccine-induced antibodies can inhibit sporozoite invasion and merozoite replication in vitro, with ongoing optimization for clinical development.

3.3. Personalized Neoantigen mRNA Cancer Vaccines

Personalized cancer vaccines represent one of the most advanced applications of epitope-based mRNA technology. BioNTech/Genentech's iNeST and Moderna's mRNA-4157 (NCT03897881) target patient-specific neoantigens identified through next-generation sequencing of tumor samples [38, 39]. The epitope selection process involves comprehensive genomic analysis to identify somatic mutations, in silico prediction of neoantigens with high MHC binding affinity, and integration into optimized mRNA constructs.

The KEYNOTE-942 Phase 2 trial evaluating mRNA-4157/V940 in combination with pembrolizumab in patients with high-risk melanoma demonstrated a statistically significant reduction in recurrence or death by 44% compared to pembrolizumab alone [40]. Based on these results, the FDA granted Breakthrough Therapy Designation for this approach in July 2023, representing the most clinically advanced epitope-based mRNA vaccine.

4. Comparative Analysis of Epitope-based Vaccine Approaches

The diverse case studies presented highlight the versatility of epitope-based mRNA vaccines across multiple pathogens and applications. This section analyzes key differences and similarities in epitope selection strategies, structural design considerations, clinical outcomes, and development status.

4.1. Epitope Selection Strategies

Different pathogens require distinct epitope selection strategies to achieve optimal immune responses. For rapidly evolving viruses like influenza and HIV, conservation analysis using Shannon entropy or similar metrics identifies regions under functional or structural constraints that limit mutation. Structure-guided selection, exemplified in RSV and HIV vaccines, focuses on specific conformations critical for neutralization. The RSV prefusion F protein and HIV Env trimers require stabilization of specific conformations to preserve key neutralizing epitopes [29, 35].

Bacterial pathogens like MTB benefit from immunopeptidomics approaches that identify naturally processed and presented epitopes, providing a more accurate prediction of in vivo recognition. For parasitic pathogens, including Plasmodium, integrating protein microarray data from naturally acquired immunity in endemic regions helps identify epitopes recognized by protective antibodies.

The most sophisticated approach involves patient-specific epitope selection based on tumor sequencing for cancer vaccines, highlighting the flexibility of the mRNA platform to deliver highly personalized immunotherapies [38, 39]. This approach has yielded

impressive clinical results in combination with immune checkpoint inhibitors, demonstrating the potential of epitope-based mRNA vaccines beyond infectious diseases.

4.2. Structural Design Considerations

Critical structural elements shared across successful epitope-based vaccines include optimized epitope arrangements, strategic linker selection, and various presentation formats to enhance immunogenicity. Linker sequences serve specific purposes: GPGPG and GGGS maintain flexibility and independent folding, AAY and EAAAK enhance proteasomal cleavage or create stable secondary structures, and KK introduces dibasic cleavage sites for endosomal processing.

Presentation strategies vary based on target epitopes and desired immune responses. Self-assembling nanoparticles (HIV eOD-GT8 60mer) increase valency and enhance B-cell activation through multivalent display. Membrane-anchored proteins (RSV F) maintain native conformation. Signal sequences direct cellular trafficking and secretion to optimize antigen presentation. Multiple approaches employ structural stabilization through strategic disulfide bonds, hydrophobic core substitutions, glycosylation engineering, and conformation-locking mutations [29, 35].

The self-amplifying RNA platform used in some constructs (Plasmodium vaccine) increases antigen expression and duration, potentially enhancing immunogenicity while reducing dose requirements. This approach may be particularly valuable for global vaccination programs where dose-sparing is economically advantageous [44].

5. Translational and Regulatory Outlook

5.1. Technical and Translational Challenges

Despite promising advances, significant challenges remain in developing effective epitope-based mRNA vaccines. Despite computational improvements, epitope prediction accuracy continues to be limited by false positives and negatives. Integration of multiple prediction algorithms and experimental validation is essential, particularly for conformational B-cell epitopes and epitopes affected by post-translational modifications [41]. Recent advancements in deep learning approaches, including AlphaFold-Multimer and ESMFold, are beginning to address these limitations by incorporating structural context into prediction pipelines [69].

Optimal epitope arrangement significantly influences processing and presentation, requiring further research to determine ideal configurations for different pathogens and host species. Epitope order can create junctional neoepitopes or interfere with processing, necessitating careful design and validation [64]. Delivery optimization remains challenging, particularly for targeted tissue distribution. LNP formulations continue to evolve, with innovations in ionizable lipids enhancing stability and cellular uptake. Novel approaches, including polymeric carriers, exosome-based delivery systems, and tissue-specific targeting moieties, show promise for improved biodistribution profiles [42].

Translating in silico predictions to in vivo efficacy requires comprehensive animal model testing before clinical advancement. Immunodominance hierarchies often differ between computational predictions and in vivo responses, requiring iterative optimization [65]. Furthermore, multiple epitopes can compete for immune recognition, with stronger epitopes potentially suppressing responses to weaker ones. Epitopes resembling self-antigens might induce tolerance rather than immunity, necessitating rigorous screening protocols [66].

5.2. Regulatory Framework Evolution

The unique nature of epitope-based vaccines presents specific regulatory challenges requiring specialized frameworks. Following COVID-19 vaccine approvals, the FDA released guidance specific to mRNA vaccines in December 2022, outlining requirements for

CMC submissions, though additional considerations for multi-epitope constructs continue to evolve [67]. The EMA PRIME program provides enhanced scientific and regulatory support for innovative vaccines addressing unmet medical needs, with specific pathways for multi-epitope designs. Though initially developed for veterinary vaccines, the WHO's DIVA guidelines offer valuable frameworks for demonstrating epitope-specific immune responses.

Key regulatory considerations for epitope-based vaccines include safety evaluation of novel linker sequences, assessment of potential junctional neoepitopes at epitope boundaries, detailed characterization of epitope presentation and processing, and appropriate immunological endpoints for epitope-specific responses. Unlike conventional vaccines, epitope-based approaches lack standardized potency assays, requiring the development of epitope-specific readouts for quality control and batch consistency [68]. Harmonizing these requirements across regulatory agencies remains an ongoing effort to facilitate global development and deployment.

Potency Assay Innovation

The lack of standardized potency assays for epitope-based vaccines represents a significant regulatory challenge. Novel approaches are emerging to address this critical gap. Multiplex epitope-specific T-cell assays such as FluoroSpot and intracellular cytokine staining panels enable simultaneous quantification of responses to multiple epitopes within a single vaccine construct. These technologies correlate functional responses with protection more accurately than traditional antibody titer measurements alone.

Surrogate neutralization assays targeting individual epitopes provide mechanistic insights into protective immunity. In contrast, quantitative mass spectrometry for epitope presentation analysis offers a precise assessment of antigen processing and presentation on target cells. Computational algorithms correlating epitope-specific responses with protection are being developed through machine learning approaches trained on clinical outcome data, enabling more refined correlates of protection for epitope-based vaccines [77].

Regulatory agencies are increasingly accepting these innovative approaches as complements to traditional potency assays, though consensus standards remain under development. Industry-academic collaborations that establish reference materials and standardized protocols will be essential for advancing epitope-based vaccine development through regulatory pathways.

5.3. Emerging Technologies and Future Applications

Several promising technologies are poised to advance epitope-based mRNA vaccine development. Advanced machine learning approaches, including large language models (e.g., BioNeMo) and structural prediction algorithms, improve epitope prediction accuracy by integrating sequence, structure, and experimental validation data [43, 69]. Self-amplifying mRNA platforms enhance immunogenicity through increased antigen expression and duration, potentially reducing dose requirements and improving cost-effectiveness for global vaccination initiatives [44].

Personalized approaches leveraging computational advances enable vaccine design tailored to individual HLA profiles, which is particularly relevant for cancer immunotherapy. Integration with long-read sequencing technologies facilitates comprehensive neoepitope discovery from patient samples [70]. Multi-pathogen epitope mosaics represent a revolutionary approach combining epitopes from multiple pathogens into single vaccines, potentially transforming vaccination schedules by protecting against various diseases with fewer administrations [71]. Early research on mosaic constructs incorporating epitopes from influenza, RSV, and coronaviruses shows promising results in preclinical models, with Moderna's mRNA-1230 leading clinical development in this area.

Real-time genomic surveillance integration provides continuous pathogen monitoring to inform rapid epitope-based vaccine updates. This approach enables ongoing refinement of epitope selection based on circulating strains and emerging immune escape variants [72]. Artificial intelligence systems integrating surveillance data, epitope prediction, and clinical outcomes could facilitate rapid vaccine adaptation for emerging threats. Targeting highly conserved epitopes across multiple strains or species may lead to universal vaccine development against rapidly evolving pathogens, with computational tools analyzing evolutionary patterns to identify epitopes conserved over extended periods [46].

Figure 1 illustrates the comprehensive pipeline for epitope-based mRNA vaccine development, integrating computational prediction, experimental validation, structural design, manufacturing, and clinical development.

6. Conclusion

Epitope-based mRNA vaccines represent a revolutionary frontier in vaccine development, combining the precision of rational epitope targeting with mRNA technology's flexibility and rapid production capabilities. The diverse case studies presented in this review demonstrate the versatility of this platform across viral, bacterial, and parasitic pathogens, as well as cancer applications, highlighting different approaches to epitope selection, structural design, and clinical implementation.

The success of mRNA-1345 against RSV and personalized cancer vaccines such as Moderna's mRNA-4157 provides compelling validation for epitope-based mRNA vaccines. At the same time, ongoing development for HIV, tuberculosis, dengue, and malaria demonstrates the broad applicability of this approach. Key advances in computational epitope prediction, structural optimization, and delivery technologies have overcome many initial challenges. However, essential hurdles in prediction accuracy, epitope arrangement, and translation to in vivo efficacy remain.

Integrating advanced artificial intelligence approaches, including AlphaFold-Multimer and large language models, with comprehensive structural biology insights has dramatically improved epitope prediction capabilities. Next-generation delivery systems, including targeted LNPs, polymeric carriers, and self-amplifying RNA constructs, continue to enhance immunogenicity while reducing dose requirements. The convergence of these technologies with real-time genomic surveillance systems establishes a foundation for rapid response to emerging pathogen threats through accelerated epitope-based vaccine design.

Manufacturing innovations addressing scale-up challenges in GMP-compliant mRNA production and formulation have significantly advanced the commercial viability of these vaccines. The evolving regulatory landscape, with guidance documents specifically addressing mRNA vaccines, provides clearer pathways to approval while ensuring appropriate safety and efficacy standards.

Future developments in multi-pathogen epitope mosaics, personalized vaccine approaches, and universal vaccine strategies hold tremendous promise for addressing emerging infectious threats and persistent global health challenges. As research continues and clinical experience expands, epitope-based mRNA vaccine technology stands poised to transform vaccination strategies across diverse disease areas, potentially ushering in a new era of precise, rationally designed immunoprophylaxis and immunotherapy.

7. Tables and Figures

Table 1: Comparative Analysis of Epitope-based mRNA Vaccines. This table summarizes key characteristics of representative epitope-based mRNA vaccines targeting

diverse pathogens and disease states, highlighting different approaches to epitope selection, presentation formats, and current development status.

Vaccine	Pathogen/Disease	Developer	Epitope Types	Selection Method	Vaccine Format	Trial Phase
mRNA-1345	RSV	Moderna (US)	Prefusion F protein epitopes	Structure-guided	Stabilized protein	FDA Approved
Tetravalent DENV	Dengue	University Researchers (Pakistan)	B-cell epitopes & T-cell epitopes (CD4+/CD8+)	Conservation analysis	Poly-epitope string	Preclinical
eOD-GT8 60mer	HIV-1	IAVI/Scripps/Moderna (US)	B-cell epitopes	Germline-targeting	Nanoparticle	Phase 1
mRNA-1230	COVID/Flu/RSV	Moderna (US)	Multiple viral antigens	Structure-guided/Conservation	Multi-pathogen mosaic	Phase 1/2
Plasmodium multi-epitope	Malaria	Academic Consortium	B-cell epitopes & T-cell epitopes	Microarray/Conservation	Self-amplifying RNA	Preclinical
MTbVAC-mRNA	Tuberculosis	BioNTech (Germany)	Immunodominant T-cell epitopes	Immunopeptidomics	Poly-epitope string	Phase 1
mRNA-4157	Melanoma	Moderna/Merck (US)	Neoantigens (CD4+ T-cell epitopes/CD8+ T-cell epitopes)	Personalized tumor sequencing	Poly-epitope string	Phase 2

Table 2: Computational Tools and Databases for Epitope Prediction. This table presents major prediction algorithms, their methodological approaches, performance metrics, and key limitations in epitope identification for vaccine design.

Tool/Database	Type	Algorithm	Performance	Limitations
NetMHCpan-4.1 [49]	MHC-I binding	Neural networks	AUC 0.91-0.95	Limited to specific species
IEDB 2023 [50]	Comprehensive	Multiple methods	Varies by method	Data gaps for rare HLA alleles
BepiPred-2.0 [51]	B-cell epitope	Random forest	AUC 0.57-0.62	Lower accuracy for conformational epitopes
VaxiJen [16]	Antigenicity	Auto cross-covariance	70-89% accuracy	Limited pathogen coverage
AllerTOP [52]	Allergenicity	k-nearest neighbors	85.3% accuracy	May miss novel allergens
AlphaFold-Multimer [69]	Structure prediction	Deep learning	1-2Å RMSD	Computationally intensive



Figure 1: Epitope-based mRNA Vaccine Development Pipeline. This figure illustrates the comprehensive development pathway from computational prediction through clinical implementation. It shows the iterative workflow, including (1) Computational epitope prediction using multiple algorithms, (2) Structural validation and optimization, (3) Experimental validation, (4) mRNA construct design, (5) Manufacturing process, (6) Delivery system optimization; (7) Preclinical testing; and (8) Clinical development phases. The arrows indicate feedback loops between stages and integration points for emerging technologies.

8. Glossary of Abbreviations

Abbreviation	Full Term
ADE	Antibody-Dependent Enhancement
AUC	Area Under the Curve
BCG	Bacillus Calmette-Guérin
bNAb	Broadly Neutralizing Antibody
CAI	Codon Adaptation Index
CD4+	Cluster of Differentiation 4 Positive
CD8+	Cluster of Differentiation 8 Positive
CFP-10	Culture Filtrate Protein 10
CMC	Chemistry, Manufacturing, and Controls
CSP	Circumsporozoite Protein
DENV	Dengue Virus
DIVA	Differentiation of Infected from Vaccinated Animals

EAAAK	Glutamic Acid-Alanine-Alanine-Alanine-Lysine (linker sequence)
ELISA	Enzyme-Linked Immunosorbent Assay
ELISPOT	Enzyme-Linked Immunospot
EMA	European Medicines Agency
Env	Envelope protein
ESAT-6	Early Secreted Antigenic Target 6
FDA	Food and Drug Administration
GPGPG	Glycine-Proline-Glycine-Proline-Glycine (linker sequence)
GGGS	Glycine-Glycine-Glycine-Serine (linker sequence)
GMP	Good Manufacturing Practice
HA	Hemagglutinin
HCV	Hepatitis C Virus
HIV	Human Immunodeficiency Virus
HLA	Human Leukocyte Antigen
IEDB	Immune Epitope Database
IFN-γ	Interferon-gamma
iNeST	Individualized Neoantigen Specific Immunotherapy
KK	Lysine-Lysine (linker sequence)
LNP	Lipid Nanoparticle
MERS-CoV	Middle East Respiratory Syndrome Coronavirus
MHC	Major Histocompatibility Complex
MSP1	Merozoite Surface Protein 1
MTB	Mycobacterium tuberculosis
m1Ψ	N1-methylpseudouridine
NA	Neuraminidase
ORF	Open Reading Frame
PADRE	Pan HLA DR-binding Epitope
PLAT	Plasminogen Activator, Tissue type
PRIME	Priority Medicines (EMA program)
RBD	Receptor-Binding Domain
RMSD	Root Mean Square Deviation
RSV	Respiratory Syncytial Virus
TET	Tetanus Toxin Epitope
TPA	Tissue Plasminogen Activator
TRAP	Thrombospondin-Related Anonymous Protein
UTR	Untranslated Region
WHO	World Health Organization
Ψ	Pseudouridine

9. References

1. Bhatia B, Sonar S, Khan S, Bhattacharya J. Pandemic-Proofing: Intercepting Zoonotic Spillover Events. Pathogens. 2024;13(12):1067. https://doi.org/10.3390/pathogens13121067
2. Nii-Trebi NI, Mughogho TS, Abdulai A, et al. Dynamics of Viral Disease Outbreaks: A Hundred Years (1918/19--2019/20) in Retrospect - Loses, Lessons and Emerging Issues. Rev Med Virol. 2023;33(6) . https://doi.org/10.1002/rmv.2475
3. Montero DA, Vidal RM, Velasco J, et al. Two Centuries of Vaccination: Historical and Conceptual Approach and Future Perspectives. Front Public Health. 2024;11:1326154. https://doi.org/10.3389/fpubh.2023.1326154

4. Alanazi FTH, Alharbi BN, Aljuaid TH, et al. The Impact of Vaccinations on Disease Prevention: A Comprehensive Analysis of Their Role in Enhancing Global Public Health and Reducing Morbidity and Mortality Rates. Int J Health Sci (Qassim). 2024;8:1885-1907.
5. Bedi R, Bayless NL, Glanville J. Challenges and Progress in Designing Broad-Spectrum Vaccines Against Rapidly Mutating Viruses. Annu Rev Biomed Data Sci. 2023;6:419-441. https://doi.org/10.1146/annurev-biodatasci-030422-123201
6. Ghattas M, Dwivedi G, Lavertu M, Alameh M-G. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines (Basel). 2021;9:1490. https://doi.org/10.3390/vaccines9121490
7. Al Fayez N, Nassar MS, Alshehri AA, et al. Recent Advancement in MRNA Vaccine Development and Applications. Pharmaceutics. 2023;15(7):1972. https://doi.org/10.3390/pharmaceutics15071972
8. Leong KY, Tham SK, Poh CL. Revolutionizing Immunization: A Comprehensive Review of MRNA Vaccine Technology and Applications. Virol J. 2025;22(1):71. https://doi.org/10.1186/s12985-025-02645-6
9. Hsiung K-C, Chiang H-J, Reinig S, Shih S-R. Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions. Vaccines (Basel). 2024;12(3):1345. https://doi.org/10.3390/vaccines12031345
10. Villa TG, Abril AG, Sánchez S, de Miguel T, Sánchez-Pérez A. Animal and Human RNA Viruses: Genetic Variability and Ability to Overcome Vaccines. Arch Microbiol. 2021;203:443-464. https://doi.org/10.1007/s00203-020-02054-z
11. Norris SJ, Brangulis K. Meta-Analysis of the Vmp-like Sequences of Lyme Disease Borrelia: Evidence for the Evolution of an Elaborate Antigenic Variation System. Front Microbiol. 2024;15:1363214. https://doi.org/10.3389/fmicb.2024.1363214
12. Oli AN, Obialor WO, Ifeanyichukwu MO, et al. Immunoinformatics and Vaccine Development: An Overview. Immunotargets Ther. 2020;9:13-30. https://doi.org/10.2147/ITT.S241064
13. Jaishwal P, Jha K, Singh SP. Revisiting the Dimensions of Universal Vaccine with Special Focus on COVID-19: Efficacy versus Methods of Designing. Int J Biol Macromol. 2024;277:134012. https://doi.org/10.1016/j.ijbiomac.2024.134012
14. Khalaf WS, Morgan RN, Elkhatib WF. Clinical Microbiology and Artificial Intelligence: Different Applications, Challenges, and Future Prospects. J Microbiol Methods. 2025;232-234:107125. https://doi.org/10.1016/j.mimet.2025.107125
15. Kalita P, Tripathi T. Methodological Advances in the Design of Peptide-Based Vaccines. Drug Discov Today. 2022;27:1367-1380. https://doi.org/10.1016/j.drudis.2021.12.002
16. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8(1):4. https://doi.org/10.1186/1471-2105-8-4
17. Herrera-Ong LR. Strategic Construction of MRNA Vaccine Derived from Conserved and Experimentally Validated Epitopes of Avian Influenza Type A Virus: A Reverse Vaccinology Approach. Clin Exp Vaccine Res. 2023;12:156-171. https://doi.org/10.7774/cevr.2023.12.2.156
18. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006;7(1):1-5. https://doi.org/10.1186/1471-2105-7-153
19. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2---a server for in silico prediction of allergens. Journal of Molecular Modeling. 2014;20(6):2278. https://doi.org/10.1007/s00894-014-2278-5
20. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Research. 2017;45(W1) . https://doi.org/10.1093/nar/gkx346

21. Drazkowska K, Tomecki R, Warminski M, et al. 2'-O-Methylation of the second transcribed nucleotide within the mRNA 5' cap impacts the protein production level in a cell-specific manner and contributes to RNA immune evasion. Nucleic Acids Research. 2022;50(16):9051-9071. https://doi.org/10.1093/nar/gkac679
22. Dhungel P, Cao S, Yang Z. The 5'-poly(A) leader of poxvirus mRNA confers a translational advantage that can be achieved in cells with impaired cap-dependent translation. PLoS Pathogens. 2017;13(8) . https://doi.org/10.1371/journal.ppat.1006602
23. Grote A, Hiller K, Scheer M, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Research. 2005;33(Web Server issue) . https://doi.org/10.1093/nar/gki376
24. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Medicine. 2017;9(1):60. https://doi.org/10.1186/s13073-017-0450-0
25. Kim SC, Sekhon SS, Shin WR, et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Molecular and Cellular Toxicology. 2022;18(1):1-8. https://doi.org/10.1007/s13273-021-00171-4
26. Mia MM, Hasan M, Ahmed S, Rahman MN. Insight into the first multi-epitope-based peptide subunit vaccine against avian influenza A virus (H5N6): An immunoinformatics approach. Infection, Genetics and Evolution. 2022;104:105355. https://doi.org/10.1016/j.meegid.2022.105355
27. Russell CJ, Simões EA, Hurwitz JL. The search for a respiratory syncytial virus vaccine. Trends Mol Med. 2024;30(3):187-201. https://doi.org/10.1016/j.molmed.2023.12.001
28. Moderna. Moderna announces positive interim phase 1 data for its RSV vaccine. Press Release. 2022;Apr 12.
29. Graham BS, Gilman MSA, McLellan JS. Structure-based vaccine antigen design. Annu Rev Med. 2024;75:217-235. https://doi.org/10.1146/annurev-med-042921-091442
30. Swanson KA, Settembre EC, Shaw CA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA. 2023;108(23):9619-9624. https://doi.org/10.1073/pnas.1115941108
31. Moderna. Moderna announces FDA approval of ABRYSVO™ (mRNA-1345), the first mRNA vaccine for the prevention of RSV in adults aged 60 years and older. Press Release. 2024;Aug 8.
32. Mukhtar M, Wajeeha AW, Zaidi NUS, Bibi N. Engineering Modified MRNA-Based Vaccine against Dengue Virus Using Computational and Reverse Vaccinology Approaches. Int J Mol Sci. 2022;23:13911. https://doi.org/10.3390/ijms232213911
33. Jardine JG, Ota T, Sok D, et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2023;351(6280):1458-63. https://doi.org/10.1126/science.aad9195
34. Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 2024;19(11):1179-1188. https://doi.org/10.1038/s41590-018-0235-7
35. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2024;340(6133):711-6. https://doi.org/10.1126/science.1234150
36. Cohen J. Experimental vaccine primes human immune system to make effective antibodies against HIV. Science. 2024;Feb 24:doi:10.1126/science.adi8224.
37. Bagherzadeh MA, Izadi M, Baesi K, Jahromi MAM, Pirestani M. Considering Epitopes Conservity in Targeting SARS-CoV-2 Mutations in Variants: A Novel Immunoinformatics Approach to Vaccine Design. Sci Rep. 2022;12:14017. https://doi.org/10.1038/s41598-022-18241-5
38. Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2024;375(6576):1005-1010. https://doi.org/10.1126/science.aaw2391
39. Moderna. Moderna announces clinical update on personalized cancer vaccine program. Press Release. 2023;Dec 13.

40. Moderna, Merck. Results from Moderna and Merck's Individualized Neoantigen Therapy mRNA-4157/V940 in Combination with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting. Press Release. 2023;Apr 16.
41. Galanis KA, Nastou KC, Papandreou NC, et al. Linear B-cell epitope prediction for in silico vaccine design: a performance review of methods available via command-line interface. International Journal of Molecular Sciences. 2022;22(6):3210. https://doi.org/10.3390/ijms22063210
42. Rohner E, Yang R, Foo KS, et al. Unlocking the promise of mRNA therapeutics. Nature Biotechnology. 2023;40(11):1586-1600. https://doi.org/10.1038/s41587-022-01491-z
43. Sette A, Crotty S. Machine learning-based prediction of T cell epitopes improves the development of personalized cancer vaccines. Science Immunology. 2023;8(84) . https://doi.org/10.1126/sciimmunol.adf4307
44. Blakney AK, McKay PF, Shattock RJ. Structural components for amplification of positive-strand RNA viruses as self-amplifying RNA vaccines. Frontiers in Immunology. 2021;12:664304. https://doi.org/10.3389/fimmu.2021.664304
45. Shibata T, Gad E, Disis ML. Personalized neoantigen mRNA vaccines for cancer immunotherapy. Genes Dis. 2023;10(4):1232-1244. https://doi.org/10.1016/j.gendis.2022.06.007
46. Nachbagauer R, Krammer F. Universal influenza virus vaccines: progress. Nat Rev Drug Discov. 2023;15(5):295-319. https://doi.org/10.1038/nrd.2016.38
47. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1) . https://doi.org/10.1093/nar/gkaa379
48. Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12) . https://doi.org/10.1371/journal.pcbi.1002829
49. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. J Immunol. 2017;199(9):3360-3368. https://doi.org/10.4049/jimmunol.1700893
50. Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1) . https://doi.org/10.1093/nar/gky1006
51. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1) . https://doi.org/10.1093/nar/gkx346
52. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2--a server for in silico prediction of allergens. J Mol Model. 2014;20(6):2278. https://doi.org/10.1007/s00894-014-2278-5
53. Alford RF, Leaver-Fay A, Jeliazkov JR, et al. The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design. J Chem Theory Comput. 2017;13(6):3031-3048. https://doi.org/10.1021/acs.jctc.7b00125
54. Baker HM, Day CL. Structure, function and dynamics in T cell receptor recognition. Curr Opin Immunol. 2021;72:146-154. https://doi.org/10.1016/j.coi.2021.07.003
55. Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107-112. https://doi.org/10.1038/s41586-020-2537-9
56. Wunderlich G, Pires CV, Alves RF, et al. Influence of B cell epitope presentation on antibody recognition of malaria proteins. Vaccine. 2020;38(45):7100-7107. https://doi.org/10.1016/j.vaccine.2020.08.041
57. Sangesland M, Ronsard L, Kazer SW, et al. Germline-Targeting HIV Vaccine Induces Naïve B Cell Responses in Humans. Cell. 2022;185(17):3319-3333.e19. https://doi.org/10.1016/j.cell.2022.07.021
58. Zhang N, Li X, Deng Y, et al. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182(5):1271-1283.e16. https://doi.org/10.1016/j.cell.2020.07.024

59. Dai L, Zheng T, Xu K, et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722-733.e11. https://doi.org/10.1016/j.cell.2020.06.035
60. Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572-577. https://doi.org/10.1038/s41586-020-2599-8
61. Chinese Academy of Sciences. China's Homegrown COVID-19 mRNA Vaccine Shows Promising Results. Press Release. 2023;Mar 15.
62. BioNTech. BioNTech Announces First Patient Dosed in Phase 1 Trial of Novel mRNA-based Vaccine Against Tuberculosis. Press Release. 2023;Jan 12.
63. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222-226. https://doi.org/10.1038/nature23003
64. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008;9:1. https://doi.org/10.1186/1471-2172-9-1
65. Kim Y, Yewdell JW, Sette A, Peters B. Positional bias of MHC class I restricted T-cell epitopes in viral antigens is likely due to a bias in conservation. PLoS Comput Biol. 2013;9(1) . https://doi.org/10.1371/journal.pcbi.1002884
66. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-219. https://doi.org/10.1007/s002510050595
67. U.S. Food and Drug Administration. Considerations for Development of mRNA COVID-19 Vaccines: Guidance for Industry. 2022 Dec.
68. Li Z, Baihaqi YA, Shu X, et al. Machine learning predicts efficient anti-cancer drug combinations based on cooperative target inhibition. Nat Commun. 2022;13(1):5560. https://doi.org/10.1038/s41467-022-33291-z
69. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589. https://doi.org/10.1038/s41586-021-03819-2
70. Zacharakis N, Chinnasamy H, Black M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724-730. https://doi.org/10.1038/s41591-018-0040-8
71. Khan AM, Miotto O, Heiny AT, et al. A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol. 2006;244(2):141-147. https://doi.org/10.1016/j.cellimm.2007.02.005
72. Daszak P, Keusch GT, Phelan AL, Johnson CK, Osterholm MT. Infectious Disease Threats: A Rebound To Resilience. Health Aff (Millwood). 2021;40(2):204-211. https://doi.org/10.1377/hlthaff.2020.01544
73. Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, and prospects. Curr Opin Immunol. 2020;65:9-16. https://doi.org/10.1016/j.coi.2020.04.006
74. Stewart-Jones GB, Soto C, Lemmin T, et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell. 2016;165(4):813-826. https://doi.org/10.1016/j.cell.2016.04.010
75. Watanabe Y, Bowden TA, Wilson IA, Crispin M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj. 2019;1863(10):1480-1497. https://doi.org/10.1016/j.bbagen.2019.05.012
76. Moderna. Moderna announces positive Phase 1/2 interim data for combination respiratory vaccine candidates. Press Release. 2024;Jan 17.
77. Sahin U, Langer M, Kreiter S, et al. A new era in epitope-specific immune readouts for vaccine development. Nat Rev Drug Discov. 2023;22(5):384-404. https://doi.org/10.1038/s41573-023-00647-z

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.